Considerations in the design and evaluation of cytotoxic estrogens

John A. Katzenellenbogen, Benita S Katzenellenbogen

Research output: Contribution to journalArticle

Abstract

The estrogen receptor that is present in many breast tumors provides a mechanism for the concentration of estrogens. Hence, it should be possible to effect a selective, receptor-mediated killing of estrogen receptor-rich tumor cells with a suitable cytotoxic estrogen derivative. Because the dose per cell that can be delivered by a receptor-mediated process is limited by the capacity of the estrogen receptor system (ca. 1,000-10,000 molecules per cell), the cytotoxic moiety of these derivatives needs to be directed at a target where an effective cell kill can be achieved with this limited dose; DNA appears to be the most suitable target. The estrogen derivatives that contain DNA-alkylating and cross-linking groups and retain high affinity for the estrogen receptor should be carried selectively to the nucleus. There, it is hoped that they would react with DNA with reasonable efficiency. Definitive tests of receptor-mediated cytotoxicity in vitro could be performed in cultures of human breast tumor cells that are receptor positive (e.g., MCF-7) or receptor negative (e.g., MDA-MB-231). These tests would involve comparison of the potency of the cytotoxic estrogens with that of cytotoxic control compounds, both in the presence and absence of estradiol, in order to correct for possible differences in the sensitivity of the different cell lines to cytotoxic agents and to metabolic effects of estradiol. These agents would then be tested in experimental mammary tumor systems in the rat. Our current understanding of the characteristics of estrogen receptor binding, and the availability of suitable systems for studying these agents in vitro and in vivo, make a definitive test of selective cytotoxicity, mediated by the estrogen receptor, a timely and sensible endeavor.

Original languageEnglish (US)
Pages (from-to)347-353
Number of pages7
JournalBreast Cancer Research and Treatment
Volume2
Issue number4
DOIs
StatePublished - Dec 1 1982

Fingerprint

Estrogen Receptors
Estrogens
Breast Neoplasms
Estradiol
DNA
Cytotoxins
Cell Line
Neoplasms
In Vitro Techniques

Keywords

  • DNA-target for cytotoxicity
  • MCF-7 cells
  • MDA-MB-231 cells
  • antiestrogens
  • cytotoxic estrogens
  • estrogen receptor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Considerations in the design and evaluation of cytotoxic estrogens. / Katzenellenbogen, John A.; Katzenellenbogen, Benita S.

In: Breast Cancer Research and Treatment, Vol. 2, No. 4, 01.12.1982, p. 347-353.

Research output: Contribution to journalArticle

@article{7a4259a9f3974a3ba8c2aba76166d80c,
title = "Considerations in the design and evaluation of cytotoxic estrogens",
abstract = "The estrogen receptor that is present in many breast tumors provides a mechanism for the concentration of estrogens. Hence, it should be possible to effect a selective, receptor-mediated killing of estrogen receptor-rich tumor cells with a suitable cytotoxic estrogen derivative. Because the dose per cell that can be delivered by a receptor-mediated process is limited by the capacity of the estrogen receptor system (ca. 1,000-10,000 molecules per cell), the cytotoxic moiety of these derivatives needs to be directed at a target where an effective cell kill can be achieved with this limited dose; DNA appears to be the most suitable target. The estrogen derivatives that contain DNA-alkylating and cross-linking groups and retain high affinity for the estrogen receptor should be carried selectively to the nucleus. There, it is hoped that they would react with DNA with reasonable efficiency. Definitive tests of receptor-mediated cytotoxicity in vitro could be performed in cultures of human breast tumor cells that are receptor positive (e.g., MCF-7) or receptor negative (e.g., MDA-MB-231). These tests would involve comparison of the potency of the cytotoxic estrogens with that of cytotoxic control compounds, both in the presence and absence of estradiol, in order to correct for possible differences in the sensitivity of the different cell lines to cytotoxic agents and to metabolic effects of estradiol. These agents would then be tested in experimental mammary tumor systems in the rat. Our current understanding of the characteristics of estrogen receptor binding, and the availability of suitable systems for studying these agents in vitro and in vivo, make a definitive test of selective cytotoxicity, mediated by the estrogen receptor, a timely and sensible endeavor.",
keywords = "DNA-target for cytotoxicity, MCF-7 cells, MDA-MB-231 cells, antiestrogens, cytotoxic estrogens, estrogen receptor",
author = "Katzenellenbogen, {John A.} and Katzenellenbogen, {Benita S}",
year = "1982",
month = "12",
day = "1",
doi = "10.1007/BF01805876",
language = "English (US)",
volume = "2",
pages = "347--353",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Considerations in the design and evaluation of cytotoxic estrogens

AU - Katzenellenbogen, John A.

AU - Katzenellenbogen, Benita S

PY - 1982/12/1

Y1 - 1982/12/1

N2 - The estrogen receptor that is present in many breast tumors provides a mechanism for the concentration of estrogens. Hence, it should be possible to effect a selective, receptor-mediated killing of estrogen receptor-rich tumor cells with a suitable cytotoxic estrogen derivative. Because the dose per cell that can be delivered by a receptor-mediated process is limited by the capacity of the estrogen receptor system (ca. 1,000-10,000 molecules per cell), the cytotoxic moiety of these derivatives needs to be directed at a target where an effective cell kill can be achieved with this limited dose; DNA appears to be the most suitable target. The estrogen derivatives that contain DNA-alkylating and cross-linking groups and retain high affinity for the estrogen receptor should be carried selectively to the nucleus. There, it is hoped that they would react with DNA with reasonable efficiency. Definitive tests of receptor-mediated cytotoxicity in vitro could be performed in cultures of human breast tumor cells that are receptor positive (e.g., MCF-7) or receptor negative (e.g., MDA-MB-231). These tests would involve comparison of the potency of the cytotoxic estrogens with that of cytotoxic control compounds, both in the presence and absence of estradiol, in order to correct for possible differences in the sensitivity of the different cell lines to cytotoxic agents and to metabolic effects of estradiol. These agents would then be tested in experimental mammary tumor systems in the rat. Our current understanding of the characteristics of estrogen receptor binding, and the availability of suitable systems for studying these agents in vitro and in vivo, make a definitive test of selective cytotoxicity, mediated by the estrogen receptor, a timely and sensible endeavor.

AB - The estrogen receptor that is present in many breast tumors provides a mechanism for the concentration of estrogens. Hence, it should be possible to effect a selective, receptor-mediated killing of estrogen receptor-rich tumor cells with a suitable cytotoxic estrogen derivative. Because the dose per cell that can be delivered by a receptor-mediated process is limited by the capacity of the estrogen receptor system (ca. 1,000-10,000 molecules per cell), the cytotoxic moiety of these derivatives needs to be directed at a target where an effective cell kill can be achieved with this limited dose; DNA appears to be the most suitable target. The estrogen derivatives that contain DNA-alkylating and cross-linking groups and retain high affinity for the estrogen receptor should be carried selectively to the nucleus. There, it is hoped that they would react with DNA with reasonable efficiency. Definitive tests of receptor-mediated cytotoxicity in vitro could be performed in cultures of human breast tumor cells that are receptor positive (e.g., MCF-7) or receptor negative (e.g., MDA-MB-231). These tests would involve comparison of the potency of the cytotoxic estrogens with that of cytotoxic control compounds, both in the presence and absence of estradiol, in order to correct for possible differences in the sensitivity of the different cell lines to cytotoxic agents and to metabolic effects of estradiol. These agents would then be tested in experimental mammary tumor systems in the rat. Our current understanding of the characteristics of estrogen receptor binding, and the availability of suitable systems for studying these agents in vitro and in vivo, make a definitive test of selective cytotoxicity, mediated by the estrogen receptor, a timely and sensible endeavor.

KW - DNA-target for cytotoxicity

KW - MCF-7 cells

KW - MDA-MB-231 cells

KW - antiestrogens

KW - cytotoxic estrogens

KW - estrogen receptor

UR - http://www.scopus.com/inward/record.url?scp=0020282678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020282678&partnerID=8YFLogxK

U2 - 10.1007/BF01805876

DO - 10.1007/BF01805876

M3 - Article

VL - 2

SP - 347

EP - 353

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 4

ER -